Transparency data

Non-tech. summaries 2015: projects on nervous system and mental disorders

Projects granted during 2015 that have a primary purpose of translational and applied research: human nervous system and mental disorders.


Non-technical summaries: projects granted in 2015, volume 14

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2015 with a primary purpose of translational and applied research: human nervous system and mental disorders.

The following projects were granted:

  • white matter and glial function and pathology (glia, astrocyte, oligodendrocyte, white matter, nervous system)
  • improving translation in Parkinson’s disease (cell transplantation, side effects, disease models)
  • brain mechanisms of cognition and behaviour (brain, cognition, behaviour, rats)
  • brain injury and repair (brain, stroke, optic nerve, plasticity, neuronal growth)
  • disruption of biological rhythms and stroke (stroke, hyperglycemia, hypertension, obesity, circadian rhythm)
  • neuroprotective effects of novel incretin analogues in models of Parkinson’s disease (Parkinson’s disease, rigor, tremor, drug development, dopamine)
  • studies of transgenic rodents that express human amyloid protein (Transgenic, rodents, human, amyloid, protein)
  • bioelectronic medicines (electrophysiology, implantable devices)
  • DNA strand breaks, DNA damage responses, and disease (DNA damage, neurodegeneration, cancer)
  • understanding rare intellectual disability syndromes (cerebellar atrophy, ataxia, bone mineralisation, hyperostosis, intellectual disability)
  • drug development in Dravet syndrome (epilepsy, Dravet syndrome, seizures, drug development)
  • the development of vaccine against specific domains of NMDAR to allow pre-treatment of patients at high risk of stroke (stroke, vaccine)
  • therapies in Parkinson’s and Huntington’s disease (neurodegenerative disease model, treatment, behaviour)
  • role of the environment in drug abuse development (drug abuse, rat, environment, context)
  • preclinical screening in drug discovery (imaging, drug discovery, disease models)
  • physiology and pathophysiology of motor circuitry (zebrafish, electrophysiology, motor network)
  • sheep as a large animal models in health and disease (Huntington disease, sheep, behaviour, electrophysiology)
  • understanding locomotor control mechanisms (locomotor circuit, development, neuroregeneration, electrophysiology)
  • mechanisms underlying Rett syndrome and other autism spectrum disorders (sensory processing, Rett syndrome, EEG, neurons, autism)
  • regulation of body glucose and energy levels by the brain (diabetes, obesity, glucose, energy, brain)
  • developing in vivo Raman spectroscopy in mice (Raman spectroscopy, neuromuscular disease)
  • mutations in matrix proteins and disease (stroke, vascular disease, collagen)
  • molecular mechanisms underlying neurogenesis and neurodegeneration (nervous system, neurodegeneration, mouse models)
  • new medicines for amyloid and C-reactive protein (amyloidosis, serum amyloid P component, monoclonal antibody, immunotherapy, drug development)
  • brain protection for birth asphyxia (birth asphyxia, brain protection, newborn, therapeutic hypothermia)
  • protein function in genetically altered and stroke mice (brain, stroke, brain compounds, receptors)
  • therapeutic strategies in developmental disorders (neurology, autism, intellectual disability, Rett syndrome)
  • sensory feedback in artificial limbs (sensory, artificial limbs, stimulation, peripheral nerve)
  • repairing the damaged spinal cord (spinal cord injury, axon regeneration, neuroprotection, scarring, cavitation)
Published 21 June 2016